Veradermics, Incorporated (MANE)

Veradermics, Incorporated is trading at $98.46, up 0.97% on the session. The 50 day average sits at $111.10 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 40.8, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $93.81 with resistance near $114.41, so that band frames the current range. Average daily movement is roughly $6.17, or about 6.3% of the share price, which is what any stop placement has to allow for. The overall health score of 33 out of 100 combines a trend score of 32, momentum of 25 and a risk score of 44.

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.